NATALEE 6-y results are out! #ESMO26
2.1 delta in survival at 6 years.
Thanks @Annals_Oncology for reporting subsequent therapy data!
👉Only 44.4% of control arm patients with distant recurrence received a first-line CDK4/6i
Does this survival difference truly inform clinical practice in settings where CDK4/6i are standard of care for metastatic disease?
In my opinion, the answer is no.
2604 浏览 · 31 赞 · 11 转发 · 2 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- douglas@deathinsep
@Timothee_MD @Annals_Oncology But if they use in second line, SONIA suggested that the overall survival benefit with iCDK in metastatic disease would be similar
- Cohen carine@carinecccc
@Timothee_MD @Annals_Oncology They hided the OS in thé Europe region alone, which represents 59% of thé whole trial, And they dropped thé table of deaths due to other causes than breast cancer to conceal the many cardiovascular events!
来源：Timothée Olivier, MD · x.com